Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NVM4
UPID:
ANM7_HUMAN
Alternative names:
Histone-arginine N-methyltransferase PRMT7; [Myelin basic protein]-arginine N-methyltransferase PRMT7
Alternative UPACC:
Q9NVM4; B3KPR0; B3KUG9; B4E379; Q96PV5; Q9H9L0
Background:
Protein arginine N-methyltransferase 7 (PRMT7) is known for its critical role in arginine methylation, impacting various biological processes. It catalyzes the formation of omega-N monomethylarginine and symmetrical dimethylarginine, with a preference for the former. PRMT7's activity is essential for the methylation of specific proteins, including histones and myelin basic protein, influencing snRNP core particle assembly, gene imprinting, and possibly embryonic stem cell pluripotency.
Therapeutic significance:
The involvement of PRMT7 in a rare autosomal recessive disease characterized by developmental delay, learning disabilities, and skeletal abnormalities highlights its potential as a therapeutic target. Understanding the role of PRMT7 could open doors to potential therapeutic strategies for treating this condition and possibly other related disorders.